132 related articles for article (PubMed ID: 32657634)
1. Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of
Suman S; Priya R; Kameswaran M
Int J Radiat Biol; 2020 Sep; 96(9):1144-1156. PubMed ID: 32657634
[TBL] [Abstract][Full Text] [Related]
2. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
Chan C; Fonge H; Lam K; Reilly RM
Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M
Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096
[TBL] [Abstract][Full Text] [Related]
5. Sensitisation of human lung adenocarcinoma A549 cells to radiotherapy by Nimotuzumab is associated with enhanced apoptosis and cell cycle arrest in the G2/M phase.
Lin S; Yan Y; Liu Y; Gao CZ; Shan D; Li Y; Han B
Cell Biol Int; 2015 Feb; 39(2):146-51. PubMed ID: 25044496
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196891
[TBL] [Abstract][Full Text] [Related]
7. A potencial theranostic agent for EGF-R expression tumors: (177)Lu-DOTA-nimotuzumab.
Calzada V; Zhang X; Fernandez M; Diaz-Miqueli A; Iznaga-Escobar N; Deutscher SL; Balter H; Quinn TP; Cabral P
Curr Radiopharm; 2012 Oct; 5(4):318-24. PubMed ID: 22280117
[TBL] [Abstract][Full Text] [Related]
8. Nimotuzumab enhances the radiosensitivity of cancer cells in vitro by inhibiting radiation-induced DNA damage repair.
Qu YY; Hu SL; Xu XY; Wang RZ; Yu HY; Xu JY; Chen L; Dong GL
PLoS One; 2013; 8(8):e70727. PubMed ID: 23976954
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
10. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors.
Vera DR; Eigner S; Henke KE; Lebeda O; Melichar F; Beran M
Nucl Med Biol; 2012 Jan; 39(1):3-13. PubMed ID: 21958849
[TBL] [Abstract][Full Text] [Related]
11. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
12. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
13.
Kumar C; Sharma R; Das T; Korde A; Sarma H; Banerjee S; Dash A
J Labelled Comp Radiopharm; 2018 Sep; 61(11):837-846. PubMed ID: 29923620
[TBL] [Abstract][Full Text] [Related]
14. Dose-dependent cell cycle arrest and apoptosis in HER2 breast cancer cells by
Sharma R; Kameswaran M; Pandey U; Dash A
J Cancer Res Ther; 2020; 16(6):1426-1434. PubMed ID: 33342808
[TBL] [Abstract][Full Text] [Related]
15. (131)I-Nimotuzumab - A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR.
Kameswaran M; Samuel G; Dev Sarma H; Shinde SN; Dash A; Venkatesh M
Appl Radiat Isot; 2015 Aug; 102():98-102. PubMed ID: 26002276
[TBL] [Abstract][Full Text] [Related]
16. (177)Lu/ (90)Y intermediate-affinity monoclonal antibodies targeting EGFR and HER2/c-neu: preparation and preclinical evaluation.
Beckford Vera DR; Eigner S; Eigner Henke K; Leyva Montaña R; Melichar F; Beran M
Recent Results Cancer Res; 2013; 194():301-17. PubMed ID: 22918766
[TBL] [Abstract][Full Text] [Related]
17. Assessment of cell death mechanisms triggered by
Azorín-Vega E; Rojas-Calderón E; Martínez-Ventura B; Ramos-Bernal J; Serrano-Espinoza L; Jiménez-Mancilla N; Ordaz-Rosado D; Ferro-Flores G
Appl Radiat Isot; 2018 Aug; 138():73-77. PubMed ID: 28434643
[TBL] [Abstract][Full Text] [Related]
18. Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer.
Phaeton R; Jiang Z; Revskaya E; Fisher DR; Goldberg GL; Dadachova E
Cancer Med; 2016 Jan; 5(1):9-16. PubMed ID: 26625938
[TBL] [Abstract][Full Text] [Related]
19. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to
Aghevlian S; Cai Z; Lu Y; Hedley DW; Winnik MA; Reilly RM
Mol Pharm; 2019 Feb; 16(2):768-778. PubMed ID: 30589553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
